In the Pharmaceutical Industry the Pain Drug Market is Expected to Be Worth $25 Billion over the Next Few Years.

Research and Markets (http://www.researchandmarkets.com/reports/c31301) has announced the addition of Pain Drugs: Problems and Opportunities to their offering.
Pain is one of the largest pharmaceutical markets, forecast to reach $25 billion in the next few years, but it has also been plagued by problems including the failure of Vioxx and Celebrex. This report examines the nature of pain, what went wrong with the COX-2 inhibitors, and the alternative approaches and drugs that may fill the resulting void.
Pain comes in many forms and treatments range from non-drug therapies like psychological, surgical and neurostimulus, to analgesics, opiods and even cannabinoids. This report explores these various methods and identifies drugs currently on the market or under development that may replace the COX-2 inhibitors.
Reasons to Purchase
-- Understand the nature of pain and why it is a therapeutic challenge
-- Identify the companies and the drugs and treatment protocols that are poised to replace the void left by the failure of COX-2 inhibitors
-- Analyze the competitive landscape of the $25 billion pain market
Target Audience
-- Business development execs/managers seeking partnership opportunities
-- Marketing and senior execs/managers wishing to understand the competitive landscape
-- Research and development execs/managers wanting to know the current state-of-the-art
-- Venture capitalists and fund managers seeking investments
-- Analysts and journalists researching the market for treating pain
-- Others seeking to understand the driving factors and market dynamics
Drugs Mentioned
-- Carbex
-- Celebrex
-- Codeine
-- Imitrex
-- Luvox
-- Marplan
-- Nardil
-- Neurontin
-- OxyContin
-- Parnate
-- Paxil
-- Prozac
-- Topamax
-- Tylenol/Acetaminophen
-- Vicodin
-- Vioxx
-- - Xyrem
-- Zarontin
-- Zoloft
-- Zomig
Topics Covered
Introduction
The Nature of Pain
Pain's Many Forms
-- Acute Pain
-- Internal Organs
-- Migraine Headache
-- Cluster Headache
-- Chronic Pain
-- Neuropathic Pain and Cancer Pain
-- Phantom Limb Pain and Other Manifestations
Treatment - Non-drug
-- Psychological
-- Local and Regional Methods
-- Surgery
-- Sympathetic Blockade
-- Neurostimulatory Methods
-- Anesthesia Pumps
Treatment - Drugs
-- Non-opioid (non-narcotic) Analgesics
-- Opioids (narcotics)
-- Tranquilizers
Non-painkiller Drugs
-- Anti-epileptics
-- Antidepressants
-- Cannabinoids
Companies Mentioned
Abbott
Pfizer
Purdue
Merck
Medtronic
Janssen-Cilag
Johnson & Johnson
Takeda
For more information visit http://www.researchandmarkets.com/reports/c31301